Compare NTCT & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTCT | AUPH |
|---|---|---|
| Founded | 1984 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.6B |
| IPO Year | 1999 | 1999 |
| Metric | NTCT | AUPH |
|---|---|---|
| Price | $27.77 | $15.72 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $32.00 | $17.25 |
| AVG Volume (30 Days) | 492.9K | ★ 1.6M |
| Earning Date | 01-29-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.24 | 0.55 |
| Revenue | ★ $862,770,000.00 | $265,808,000.00 |
| Revenue This Year | $5.90 | $21.22 |
| Revenue Next Year | $2.62 | $15.40 |
| P/E Ratio | ★ $22.19 | $28.81 |
| Revenue Growth | 9.60 | ★ 20.62 |
| 52 Week Low | $18.12 | $6.55 |
| 52 Week High | $30.67 | $16.48 |
| Indicator | NTCT | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 56.70 | 57.76 |
| Support Level | $27.44 | $15.15 |
| Resistance Level | $28.20 | $16.03 |
| Average True Range (ATR) | 0.53 | 0.50 |
| MACD | 0.10 | -0.12 |
| Stochastic Oscillator | 76.37 | 57.02 |
NetScout Systems Inc is a provider of service assurance and cybersecurity solutions to enterprise and government networks. It bases its solutions on proprietary adaptive service intelligence technology, which helps customers monitor and identify performance issues and provides insight into network-based security threats. These solutions also deliver real-time and historical information, which provides insight to restore service and understand the quality of user experience. The company derives revenue from the sale of network management tools and security solutions. Its geographical regions include USA, which derives maximum revenue, Europe, Asia, and Rest of the World.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.